Anixa Biosciences
ANIX
58 hedge funds and large institutions have $16.5M invested in Anixa Biosciences in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 6 closing their positions.
200% more call options, than puts
Call options by funds: $228K | Put options by funds: $76K
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
5% more funds holding
Funds holding: 55 → 58 (+3)
2.22% more ownership
Funds ownership: 14.35% → 16.56% (+2.2%)
5% less capital invested
Capital invested by funds: $17.3M → $16.5M (-$807K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.07M |
| 2 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$939K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$399K |
| 4 |
Jane Street
New York
|
+$313K |
| 5 |
Renaissance Technologies
New York
|
+$274K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$177K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$151K |
| 3 |
Morgan Stanley
New York
|
-$143K |
| 4 |
CAM
Concorde Asset Management
Ann Arbor,
Michigan
|
-$60K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$55.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Lazard Asset Management
New York
| $3K | +$4.76K | +1,194 | New |
|
52
Wells Fargo
San Francisco,
California
| $2.33K | +$36 | +9 | +1% |
|
|
LFG
53
Larson Financial Group
St Louis,
Missouri
| $1.56K | -$100 | -25 | -5% |
|
|
PCC
54
Park Circle Company
Baltimore,
Maryland
| $1.56K | – | – | – |
|
55
US Bancorp
Minneapolis,
Minnesota
| $1.25K | – | – | – |
|
56
Fidelity Investments
Boston,
Massachusetts
| $780 | +$997 | +250 | New |
|
|
BC
57
Barrett & Company
Providence,
Rhode Island
| $250 | – | – | – |
|
|
TAM
58
Tucker Asset Management
Littleton,
Colorado
| $31 | – | – | – |
|
|
CAM
59
Concorde Asset Management
Ann Arbor,
Michigan
| – | -$60K | -15,459 | Closed |
|
|
YIH
60
Y-Intercept (HK)
Hong Kong
| – | -$55.8K | -14,372 | Closed |
|
61
JP Morgan Chase
New York
| – | -$26.6K | -6,857 | Closed |
|
|
TWM
62
Tradition Wealth Management
Edina,
Minnesota
| – | -$22K | -5,600 | Closed |
|
|
LFA
63
Livelsberger Financial Advisory
Ashland,
Ohio
| – | -$6.34K | -1,634 | Closed |
|
64
Group One Trading
Chicago,
Illinois
| – | -$5.13K | -1,285 | Closed |
|
ANIX Hedge Fund Activity: Q1 2024 in Review
58 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2024, worth a combined $16.5M — down 4.7% from $17.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ANIX positions and 6 closed out — a net gain of 4 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.07M. The largest seller was UBS Group, cutting an estimated $177K.
- 58 institutional investors held Anixa Biosciences (ANIX) as of Q1 2024, up from 55 in Q4 2023.
- Funds reported $16.5M of Anixa Biosciences stock for Q1 2024, down 4.7% quarter-over-quarter.
- 10 funds opened new Anixa Biosciences positions in Q1 2024 and 6 closed out, a net change of +4 holders.
- The largest Anixa Biosciences buyer in Q1 2024 was Susquehanna International Group, an estimated $1.07M added.
- The largest Anixa Biosciences seller in Q1 2024 was UBS Group, an estimated $177K sold.
Based on aggregated 13F filings for Q1 2024.